Alnylam Pharmaceuticals Surges to Top 415 in Trading Volume with $233 Million Day

On June 5, 2025, Alnylam Pharmaceuticals (ALNY) saw a significant surge in trading volume, reaching $233 million, marking a 35.47% increase from the previous day. This placed Alnylam among the top 415 stocks by trading volume for the day. The stock price also rose by 0.88%, marking the second consecutive day of gains, with a total increase of 1.39% over the past two days.

Alnylam Pharmaceuticals has recently announced that the U.S. Food and Drug Administration (FDA) has approved its investigational drug, patisiran, for the treatment of hereditary transthyretin amyloidosis (hATTR). This approval is a significant milestone for the company, as it represents the first RNA interference (RNAi) therapeutic to receive FDA approval. The approval is based on positive results from the APOLLO Phase 3 study, which demonstrated a significant reduction in disease progression and improvement in quality of life for patients treated with patisiran.

In addition to the FDA approval, Alnylam has also announced that it has entered into a strategic collaboration with a leading biopharmaceutical company to develop and commercialize a new class of RNAi therapeutics for the treatment of cardiovascular diseases. This collaboration is expected to accelerate the development of new therapies and expand Alnylam's pipeline of innovative treatments.

Furthermore, Alnylam has reported positive interim results from its Phase 2 study of ALN-AS1, an investigational RNAi therapeutic for the treatment of alpha-1 antitrypsin deficiency (AATD). The study demonstrated a significant reduction in serum alpha-1 antitrypsin (AAT) levels and improvement in lung function for patients treated with ALN-AS1. These results are encouraging and suggest that ALN-AS1 has the potential to become a new treatment option for patients with AATD.